Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Propanc Biopharma Hosts Corporate Update Call on Recent Progress and Positive Results
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Undisclosed
Deal Type : Partnership
Propanc Biopharma Announces Strategic Pharma Partnering Initiative
Details : The partnership aims for Propanc's lead product candidate, PRP (pancreatic proenzyme), a mixture of two proenzymes, trypsinogen and chymotrypsinogen, advancing towards a Phase I, first-in-human study in advanced cancer patients.
Product Name : PRP
Product Type : Protein
Upfront Cash : Undisclosed
June 06, 2023
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in the treatment of cancer.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection for a method to treat cancer stem cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
August 16, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by IV injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
Details : PRP (chymotrypsinogen) is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable